drugset / Trial / NCT07325279
Nalmefene Implant in Healthy Subjects
Phase 1
Recruiting
24 enrolled
ReacX Pharmaceuticals, Inc.
National Institute on Drug Abuse (NIDA) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks. Additionally the pharmacokinetics (PK), how fast the drug is absorbed into the body and how long it remains in the body, will also be studies. The data collected in this healthy volunteer study will inform the Sponsor on how best to proceed with future trials in the intended patient population.
Timeline
- Start
- 2026-02-23
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nalmefene | Small molecule | — | — |